secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001628280-22-013461
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q1 net loss $14.8M vs prior-year income; reaffirms FY22 guidance
--------------------------------------------------------------------------

- Net sales $117.3M (+43.4% YoY as reported, +8.6% organic); Pain Treatments +25.3%, Restorative Therapies +57.5%, Surgical Solutions +67.6%.
- Net loss of ($14.8M) compared to net income of $24.5M in Q1 2021; Adjusted EBITDA $7.1M vs $11.1M.
- Reaffirms FY2022 guidance: net sales $545M-$565M, Adjusted EBITDA $94M-$107M.
- Cash $27.4M; debt $368.3M as of April 2, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022013461/0001628280-22-013461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022013461/bvs-20220510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-013461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer